Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Projected year of payments Projected Year of Payments [Member] Represents projected year of payments. Investments Investment, Policy [Policy Text Block] Entity Listings, Exchange [Axis] Entity Listings, Exchange [Axis] Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Schedule of expected benefit payments Schedule of Expected Benefit Payments [Table Text Block] Perry C. Siatis [Member] Perry C. Siatis Award Timing Predetermined Award Timing Predetermined [Flag] Entity File Number Entity File Number Additional paid-in capital Additional Paid-in Capital [Member] Effective Income Tax Rate Reconciliation, Tax Credit, Amount Effective Income Tax Rate Reconciliation, Tax Credit, Amount Tabular List, Table Tabular List [Table Text Block] Target investment allocations for Pension Plan (as a percent) Defined Benefit Plan, Plan Assets, Target Allocation, Percentage Supplemental Financial Information Additional Financial Information Disclosure [Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Indefinite-Lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure Indefinite-Lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure Discount rate for determining interest cost Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate Schedule of book values, approximate fair values and bases used to measure certain financial instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Cash Settled Stock Based Compensation in Connection with Acquisitions Cash Settled Stock Based Compensation in Connection with Acquisitions [Table Text Block] Cash Settled Stock Based Compensation in Connection with Acquisitions 4.70% senior notes due 2045 Senior Notes Due In 2045 At 4.70 Percent [Member] Senior Notes Due In 2045 At 4.70 Percent. Measurement Basis [Axis] Measurement Basis [Axis] Adjustment to Compensation: Adjustment to Compensation [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Schedule of weighted-average assumptions used in determining net periodic benefit cost Schedule of Weighted Average Assumptions Used to Determine Net Periodic Pension Expense [Table Text Block] Tabular disclosure of the weighted average assumptions used to determine for pension plans and/or other employee benefit plans the net benefit cost, including assumed discount rates, rate increase in compensation increase, and expected long-term rates of return on plan assets. Intangible Asset, Indefinite-Lived [Table] Intangible Asset, Indefinite-Lived [Table] Financial Instruments and Fair Value Measures Derivatives and Fair Value [Text Block] Total current taxes Current Income Tax Expense (Benefit) Senior Notes Issued in 2025 Senior Notes Issued in 2025 [Member] Senior Notes Issued in 2025 Adjustment to Compensation, Amount Adjustment to Compensation Amount Concentrations risk (as a percent) Concentration Risk, Percentage Sec 2.125 Senior Notes Due 2029 Sec 2.125 Senior Notes Due 2029 [Member] Sec 2.125 Senior Notes Due 2029 Defined benefit plans Pension Plan [Member] Short-Term Debt, Weighted Average Interest Rate, over Time Short-Term Debt, Weighted Average Interest Rate, over Time Basis of Consolidation Consolidation, Policy [Policy Text Block] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Stock Options Share-Based Payment Arrangement, Option [Member] 2029 Lease, Liability, Payments, Due Year Four Amount of lessee's undiscounted obligation for lease payments for operating and finance leases, due in fourth fiscal year following latest fiscal year. Discount rate for determining service cost Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Service Cost, Discount Rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Service Cost, Discount Rate Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Duodopa Duodopa [Member] Represents information pertaining to Duodopa, a product of the entity. Cash and Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Noncurrent finance lease liabilities balance sheet caption Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Effective Income Tax Rate Reconciliation, Percent [Abstract] Effective Income Tax Rate Reconciliation, Percent [Abstract] International - AbbVie's share of profits (included in net revenues) Collaborative Arrangements Share Of Profits Before Income Taxes Represents the amount of share of profits before income taxes under the collaborative arrangements. Ultimate per capita trend rate for health care costs from 2029 and thereafter (as a percent) Defined Benefit Plan, Ultimate Health Care Cost Trend Rate Dividends declared Dividends, Common Stock, Cash Total stockholders' equity (deficit) Equity, Attributable to Parent Measurement Frequency [Axis] Measurement Frequency [Axis] Insider Trading Policies and Procedures [Line Items] Schedule of property and equipment Property, Plant and Equipment [Table Text Block] Common stock, authorized (in shares) Common Stock, Shares Authorized 4.05% senior notes due 2039 Senior Notes Due in 2039 At 4.05 Percent [Member] Senior Notes Due in 2039 At 4.05 Percent Recurring Fair Value, Recurring [Member] Janssen Biotech, Inc Janssen Biotech Inc [Member] Represents the information pertains to the entity Janssen Biotech Inc. Liabilities and Equity Liabilities and Equity [Abstract] Cover page. Cover [Abstract] Cash and equivalents Cash and Cash Equivalents, Fair Value Disclosure Charges associated with integration or restructuring plans Restructuring and Related Cost, Incurred Cost Portion at fair value measurement Portion at Fair Value Measurement [Member] Maximum Maximum vesting period Maximum [Member] Exercisable at the end of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Amortization period Finite-Lived Intangible Asset, Useful Life Net earnings attributable to noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest Rate of compensation increases Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Net carrying amount Finite-Lived Intangible Assets, Net Finite-Lived Intangible Assets, Net Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Long-term debt Debt Instrument [Line Items] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] 5.50% senior notes due 2064 Senior Notes 5.50 Percent Due 2064 [Member] Senior Notes 5.50 Percent Due 2064 Summary of AbbVie RSA and RSU activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Earnings before income tax expense Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Entity Shell Company Entity Shell Company 3.60-3.80% aggregate notes due 2025 Aggregate notes due 2025 [Member] Aggregate notes due 2025 Cash Settled, Post-Closing Expense for Employee Incentive Awards Cash Settled, Post-Closing Expense for Employee Incentive Awards Cash Settled, Post-Closing Expense for Employee Incentive Awards Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Other restructuring Other Restructuring Plans [Member] Represents other restructuring plans. Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Schedule of Cash Flow, Supplemental Disclosures Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Comprehensive income attributable to noncontrolling interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Ozurdex Ozurdex [Member] Ozurdex Prior service cost (credit) Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Accrued balance beginning of the period Accrued balance end of the period Restructuring Reserve Income taxes payable Accrued Income Taxes, Noncurrent Domestic Income (Loss) from Continuing Operations before Income Taxes, Domestic Schedule of share-based compensation expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Approximate length of time over which accumulated gains and losses will be recognized in cost of products sold Maximum Length of Time Hedged in Cash Flow Hedge Current operating lease liabilities Operating Lease, Liability, Current Liletta and Coolsculpting Liletta and Coolsculpting [Member] Liletta and Coolsculpting Annual rate of increase in the per capita cost of covered health care obligation benefits assumed in the current year (as a percent) Defined Benefit Plan Health Care Obligations Trend Rate Assumed Current Fiscal Year Represents the assumed health care cost trend rate for the current year used to measure the expected cost of health care obligation benefits covered by the plan (gross eligible charges). Document Fiscal Period Focus Document Fiscal Period Focus Expected rate of change in compensation Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase Vyalev Vyalev [Member] Vyalev Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Derivative instruments, notional amount and fair value Derivatives, Fair Value [Line Items] 5.40% senior notes due 2054 Senior Notes 5.40 Percent Due 2054 [Member] Senior Notes 5.40 Percent Due 2054 Collaborations and Other Arrangements Collaborative Arrangement, Accounting Policy [Policy Text Block] Award Timing Method Award Timing Method [Text Block] Litigation Case Type [Domain] Litigation Case [Domain] Award Type [Axis] Award Type [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Summary of quarterly cash dividends Schedule of Dividends Payable [Table Text Block] Business Combination, Pro Forma Information Business Combination, Pro Forma Information [Table Text Block] Collaborative Arrangements and Non-collaborative Arrangement Transactions Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Share of collaboration development costs responsible by Janssen (as a percent) Collaborative Arrangements Percentage Of Share Of Development Costs Responsible By Third Party Represents the percentage of share in collaboration development costs responsible by Janssen under cost sharing arrangement. Trading Symbol Trading Symbol 2029 Lessee, Operating Lease, Liability, to be Paid, Year Four Business Combinations Business Combination [Policy Text Block] Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Stock-based compensation plans and other (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Address, City or Town Entity Address, City or Town Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation [Table Text Block] Mavyret MAVYRET [Member] Represents information pertaining to MAVYRET, a product of the entity. Weighted-average discount rate for finance leases Finance Lease, Weighted Average Discount Rate, Percent ADARx Pharmaceuticals, Inc. ADARx Pharmaceuticals, Inc. [Member] ADARx Pharmaceuticals, Inc. Effect of exchange rate changes on cash and equivalents Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Total net deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Other, primarily foreign currency translation adjustments Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount RSUs Restricted Stock Units (RSUs) [Member] Statement of Income Location, Balance [Domain] Statement of Income Location, Balance [Domain] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Total consideration Business Combination, Consideration Transferred Settlements Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Entity Emerging Growth Company Entity Emerging Growth Company 2028 Long-Term Debt, Maturity, Year Three Accumulated other comprehensive loss (income) Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax Weighted-average remaining lease term for finance leases Finance Lease, Weighted Average Remaining Lease Term Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Derivative instrument net gains (losses) recognized in the consolidated statements of earnings Derivative, Gain (Loss) on Derivative, Net 2026 Defined Benefit Plan, Expected Future Benefit Payment, Year One Restructuring reserve rollforward Restructuring Reserve [Roll Forward] Additions Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Indefinite-lived intangible assets Indefinite-Lived Intangible Assets (Excluding Goodwill) 4.549% term loan due 2027 4.549% term loan due 2027 [Member] 4.549% term loan due 2027 Less: Interest Finance Lease, Liability, Undiscounted Excess Amount Unamortized bond discounts Long Term Debt and Capital Lease Obligations Debt Instrument Unamortized Discounts Represents the amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized, as on the balance sheet date. Schedule of net revenues by product Disaggregation of Revenue [Table Text Block] Current Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Other assets Assets for Plan Benefits, Defined Benefit Plan Ubrelvy Ubrelvy [Member] Represents information pertaining to Ubrelvy, a product of the entity. Prescription drug abuse litigation in state courts Prescription Drug Abuse Litigation In State Courts [Member] Prescription Drug Abuse Litigation In State Courts Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Schedule of anticipated annual amortization expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Projected benefit obligations Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Emraclidine Emraclidine [Member] Emraclidine Share units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restatement Determination Date Restatement Determination Date Income tax expense (benefit) Tax expense (benefit) Total income tax expense (benefit) Income Tax Expense (Benefit) Debt Instrument, Basis Spread on Variable Rate Debt Instrument, Basis Spread on Variable Rate Cash flow hedging activities, tax expense (benefit) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax Preferred stock issued (in shares) Preferred Stock, Shares Issued Liletta Liletta [Member] Liletta Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Designated as hedging instrument Designated as Hedging Instrument [Member] 1.38% Senior Notes 1.38% Senior Notes [Member] 1.38% Senior Notes Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Hedging Relationship [Axis] Hedging Relationship [Axis] Cash flow hedging activities, net of tax expense (benefit) of $(18) in 2025, $16 in 2024 and $(19) in 2023 Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Net deferred tax assets (liabilities) Net deferred tax assets (liabilities) Net deferred tax assets (liabilities) Property and equipment, gross Property, Plant and Equipment, Gross Prescription Drug Abuse Litigation In State Courts In process of Being Dismissed Prescription Drug Abuse Litigation In State Courts In process of Being Dismissed [Member] Prescription Drug Abuse Litigation In State Courts In process of Being Dismissed Celsius Therapeutics Celsius Therapeutics [Member] Celsius Therapeutics Non-cash litigation reserve adjustments, net of cash payments Non-cash litigation reserve adjustments, net of cash payments Non-cash litigation reserve adjustments, net of cash payments Information For Pension Plans With An Accumulated Benefit Obligation In Excess Of Plan Assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block] Finite-Lived Intangible Assets, Fair Value Disclosure Finite-Lived Intangible Assets, Fair Value Disclosure Coolsculpting Coolsculpting [Member] Coolsculpting Restructuring Plans Restructuring and Related Activities Disclosure [Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Additions Goodwill, Acquired During Period Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Proceeds from the exercise of stock options Proceeds from Stock Options Exercised Acquisition of businesses, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Payments to Acquire Businesses, Net of Cash Acquired Income Tax Paid, Federal, after Refund Received Income Tax Paid, Federal, after Refund Received All Trading Arrangements All Trading Arrangements [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Botox Therapeutic Botox Therapeutic [Member] Represents information pertaining to Botox Therapeutic, a product of the entity. Contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Class of Treasury Stock [Table] Class of Treasury Stock [Table] Litigation and Contingencies Commitments and Contingencies, Policy [Policy Text Block] Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Percentage of outstanding common stock distributed to Abbott shareholders Percentage of Outstanding Common Stock Distributed Represents the percentage of outstanding common stock distributed to shareholders. Accumulated benefit obligation Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Cash flows from operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Amounts recognized on the consolidated balance sheets Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract] AGN-151607 AGN-151607 [Member] AGN-151607 Investments Long-Term Investments Effective Income Tax Rate Reconciliation [Table] Effective Income Tax Rate Reconciliation [Table] Preferred stock par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Estimated useful lives Property, Plant and Equipment, Useful Life Revenues from External Customers and Long-Lived Assets Revenues from External Customers and Long-Lived Assets [Line Items] Subsequent event Subsequent Event [Member] Business Combination, Recognized Asset Acquired, Other Asset, Current Business Combination, Recognized Asset Acquired, Other Asset, Current Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] PEO Total Compensation Amount PEO Total Compensation Amount Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Depreciation Depreciation expense Depreciation 1.25% Senior Euro Notes due 2024 1.25% Senior Euro Notes due 2024 [Member] 1.25% Senior Euro Notes due 2024 2029 Finance Lease, Liability, to be Paid, Year Four Fair value - Derivatives in liability position Foreign currency contracts Derivative Liability, Subject to Master Netting Arrangement, before Offset Sales rebates Accrued Sales Rebates Carrying amount as of the balance sheet date of accrued sales rebates. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized Equity Components [Axis] Equity Components [Axis] Property and Equipment Property, Plant and Equipment [Line Items] Chargebacks and rebates Chargebacks and rebates Amount before allocation of valuation allowances of deferred tax asset attributable to deductible chargebacks and rebates. Net investment hedging activities Accumulated Net Gain (Loss) From Net Investment Hedges [Member] Accumulated Net Gain (Loss) From Net Investment Hedges Prescription drug abuse litigation Prescription Drug Abuse Litigation [Member] Represents information pertaining to prescription drug abuse litigation. Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Significant unobservable input for contingent consideration Business Combination, Contingent Consideration, Liability, Measurement Input 3.20% senior notes due 2026 Senior Notes 3.20 Percent Due 2026 [Member] Represents information pertaining to the 3.20% Unsecured Senior Notes Due 2026. Deferred tax assets Components of Deferred Tax Assets [Abstract] Advertising Advertising Cost [Policy Text Block] 3.60% Senior Notes 3.60% Senior Notes [Member] 3.60% Senior Notes Entity Address, State or Province Entity Address, State or Province 2029 Defined Benefit Plan, Expected Future Benefit Payment, Year Four Pre-tax losses to be transferred into cost of products sold for foreign currency cash flow hedges during the next 12 months Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Total current liabilities Liabilities, Current Long-Term Purchase Commitment, Category of Item Purchased [Domain] Long-Term Purchase Commitment, Category of Item Purchased [Domain] Restructuring and Related Cost, Cost Incurred to Date Restructuring and Related Cost, Cost Incurred to Date Individual: Individual [Axis] Post-Employment Benefits Postemployment Benefits Disclosure [Text Block] Defined contribution plan expenses recorded Defined Contribution Plan, Cost Income Tax Jurisdiction [Domain] Income Tax Jurisdiction [Domain] Document Annual Report Document Annual Report Research and development Research and Development Expense [Member] Genentech, Inc. Genentech, Inc. [Member] Genentech, Inc. [Member] Entities [Table] Entities [Table] 4.25% senior notes due 2028 Senior Notes Due in 2028 At 4.25 Percent [Member] Senior Notes Due in 2028 At 4.25 Percent. 3.80% Senior Notes 3.80% Senior Notes [Member] 3.80% Senior Notes Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Entity Interactive Data Current Entity Interactive Data Current Absolute return funds Mutual Fund [Member] Cash balance interest crediting rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate Funded status, end of period Defined Benefit Plan, Funded (Unfunded) Status of Plan Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Current portion of long-term debt and finance lease obligations Current portion Long-Term Debt and Lease Obligation, Current Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Creon Creon [Member] Represents information pertaining to Creon, a product of the entity. Short-Term Leases Short-Term Leases [Policy Text Block] Ownership [Domain] Ownership [Domain] 2027 Finance Lease, Liability, to be Paid, Year Two Foreign exchange gain and other Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Foreign Exchange Gain (Loss) and Other, before Tax Represents the amount recognized in other comprehensive income for foreign exchange gains (losses) and other arising during the period, before tax. Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration] Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration] Restructuring costs location [Domain] Restructuring costs location [Domain] Restructuring costs location [Domain] 2027 Defined Benefit Plan, Expected Future Benefit Payment, Year Two 2027 Lease, Liability, Payments, Due Year Two Amount of lessee's undiscounted obligation for lease payments for operating and finance leases, due in second fiscal year following latest fiscal year. Other assets Other Assets, Noncurrent Customer [Domain] Customer [Domain] Entity Central Index Key Entity Central Index Key PEO Name PEO Name Immunology Immunology [Member] Represents information pertaining to Immunology, a key product portfolio of the entity. Diluted EPS Earnings Per Share, Diluted, Two Class Method [Abstract] Summary of maturities of long-term debt Schedule of Maturities of Long-Term Debt [Table Text Block] Net revenues Total net revenues Revenues Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Defined Benefit Plan [Table] Defined Benefit Plan [Table] 2.625% senior euro notes due 2028 (€500 principal) Senior Euro Notes Due 2028 At 2.625 Percent [Member] Senior Euro Notes Due 2028 At 2.625 Percent Contingent consideration liabilities Business Combination, Contingent Consideration, Liability, Noncurrent Summary of amounts and location of derivatives on the consolidated balance sheets Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Work-in-process Inventory, Work in Process, Net of Reserves Exercise Price Award Exercise Price Entity Filer Category Entity Filer Category Class of Stock [Domain] Class of Stock [Domain] Effective Income Tax Rate Reconciliation, Net Operating Loss Utilization,, Percent Effective Income Tax Rate Reconciliation, Net Operating Loss Utilization,, Percent Effective Income Tax Rate Reconciliation, Net Operating Loss Utilization,, Percent Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Benefits paid Defined Benefit Plan, Benefit Obligation, Benefits Paid Statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Subsequent Event Type [Axis] Subsequent Event Type [Axis] Current portion of contingent consideration liabilities Business Combination, Contingent Consideration, Liability, Current Statement of Financial Position Location, Balance [Axis] Statement of Financial Position Location, Balance [Axis] 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Three Oncology Oncology [Member] Represents information pertaining to Hematologic Oncology, a key product portfolio of the entity. Pre-tax gains to be transferred into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months Treasury Lock Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Treasury Rate Lock Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net U.S. large cap Defined Benefit Plan, Equity Securities, US, Large Cap [Member] Lumigan/Ganfort Lumigan/Ganfort [Member] Represents information pertaining to Lumigan/Ganfort, a product of the entity. Amortization of actuarial losses and other Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Gross carrying amount Finite-Lived Intangible Assets, Gross Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Durysta Durysta [Member] Durysta Entity Address, Address Line One Entity Address, Address Line One Accumulated other comprehensive loss AOCI Attributable to Parent AOCI Attributable to Parent [Member] Schedule of pre-tax amounts of derivatives recognized in other comprehensive income (loss) Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block] Investments [Domain] Investments [Domain] Product Liability ALCL Litigation in State Court Product Liability ALCL Litigation in State Court [Member] Product Liability ALCL Litigation in State Court Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] Post Sixty Five Years of Age Post Sixty Five Years Of Age [Member] Represents the health care cost trend rate for employees above 65 years age. Ownership [Axis] Ownership [Axis] Amortization of prior service cost Defined Benefit Plan, Amortization of Prior Service Cost (Credit) ImmunoGen ImmunoGen [Member] ImmunoGen Aesthetics Aesthetics [Member] Represents information pertaining to Aesthetics, a key product portfolio of the entity. Pension and post-employment benefits Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Other long-term liabilities Other Liabilities [Member] Fair Value as of Grant Date Award Grant Date Fair Value Operating loss carryforwards Operating Loss Carryforwards Effective Income Tax Rate Reconciliation, Tax Contingency, Amount Effective Income Tax Rate Reconciliation, Tax Contingency, Amount Fair value measured at Levels 1, 2 and 3 Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member] Summary of long-term debt Schedule of Long-Term Debt Instruments [Table Text Block] Effect of dilutive securities (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Interest rate swap contracts Interest Rate Derivative Assets, at Fair Value Total operating costs and expenses Costs and Expenses Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Summary of significant level 3 unobservable inputs Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Counterparty Name [Domain] Counterparty Name [Domain] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Two Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Germany GERMANY Schedule of accounts payable and accrued liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Investment Type [Axis] Investment Type [Axis] Title Trading Arrangement, Individual Title Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount 2028 Defined Benefit Plan, Expected Future Benefit Payment, Year Three Senior notes due 2030 at 4.875 percent Senior notes due 2030 at 4.875 percent [Member] Senior notes due 2030 at 4.875 percent Amortization of actuarial loss Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax Prepaid expenses and other Prepaid Expense and Other Assets Upfront cash payment Cash consideration paid Payments to Acquire Businesses, Gross Non-PEO NEO Non-PEO NEO [Member] Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Brazil BRAZIL Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Land Land [Member] Award Type [Domain] Award Type [Domain] Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Noncontrolling interest Equity, Attributable to Noncontrolling Interest Equity Awards Adjustments Equity Awards Adjustments [Member] Advertising expenses Advertising Expense Other, net Other Noncash Income (Expense) Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Disaggregation of Revenue Disaggregation of Revenue [Line Items] Canada CANADA Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Deferred Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Schedule of net revenues to external customers by geographic area Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Foreign currency contracts Foreign Exchange Contract [Member] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Retirement Plan Type [Domain] Retirement Plan Type [Domain] China CHINA MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Long-term debt and finance lease obligations, excluding fair value hedges Long Term Debt and Capital Lease Obligations Fair Value Disclosure Represents the fair value amount of as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year from the balance sheet date or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer plus capital lease obligations due to be paid more than one year after the balance sheet date. Effect of foreign operations Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Australia AUSTRALIA Business Combination, Recognized Asset Acquired, Deferred Tax Asset Business Combination, Recognized Asset Acquired, Deferred Tax Asset Change in fair value of contingent consideration liabilities Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease) Summary of pretax gains and losses included in other comprehensive income (loss) Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block] 2028 Lease, Liability, Payments, Due Year Three Amount of lessee's undiscounted obligation for lease payments for operating and finance leases, due in third fiscal year following latest fiscal year. Total lease payments Lease, Liability, Payments, Due Amount of lessee's undiscounted obligation for lease payments for operating and finance leases. Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Liabilities for unrecognized tax benefits Unrecognized Tax Benefits Liabilities Represents unrecognized tax benefits liabilities. Finance lease assets balance sheet caption Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Long-term debt and finance lease obligations Noncurrent portion Long-Term Debt and Lease Obligation Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration] Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration] Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] 2026 Long-Term Debt, Maturity, Year One Revolving Credit Facility Maturing 2030 Revolving Credit Facility Maturing 2030 [Member] Revolving Credit Facility Maturing 2030 Total deferred tax liabilities Deferred Tax Liabilities, Gross 2030 Long-Term Debt, Maturity, Year Five Schedule of indefinite-lived intangible assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Tax court petition Tax court petition [Member] Tax court petition BERMUDA BERMUDA Performance shares Performance Shares [Member] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Postemployment Benefits [Abstract] Postemployment Benefits [Abstract] Basic EPS Earnings Per Share, Basic, Two Class Method [Abstract] Inventories Inventories Inventory, Net Product Liability Other Litigation in Other Countries Product Liability Other Litigation in Other Countries [Member] Product Liability Other Litigation in Other Countries Developed product rights Developed Technology Rights [Member] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Minimum Minimum vesting period Minimum [Member] Earnings allocated to participating securities Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Company Selected Measure Name Company Selected Measure Name Other Other Long Term Debt [Member] Represents information pertaining to other long-term debts. Fair Value Measurement [Domain] Fair Value Measurement [Domain] Business Combination, Pro Forma Information, Pro Forma Income (Loss), after Tax Business Combination, Pro Forma Information, Pro Forma Income (Loss), after Tax Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Accounts payable Accounts Payable, Current Operating cash flows from operating leases Operating Lease, Payments Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Other individually insignificant arrangements Other Collaboration Arrangements [Member] Represents information relating to the series of other collaborative arrangements. Earnings available to common shareholders Net Income (Loss) Available to Common Stockholders, Diluted Elahere Elahere [Member] Elahere Impairment of intangible assets Impairment of Intangible Assets (Excluding Goodwill) Foreign Current Foreign Tax Expense (Benefit) Changes in the carrying amount of goodwill Goodwill [Roll Forward] Restructuring Plan [Domain] Restructuring Plan [Domain] Weighted-average diluted shares outstanding (in shares) Weighted-average diluted shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Total fair value of options vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] U.S. mid cap Defined Benefit Plan, Equity Securities, US, Mid Cap [Member] Derivative [Table] Derivative [Table] Business Combination, Recognized Liability Assumed, Long-Term Debt, Current Business Combination, Recognized Liability Assumed, Long-Term Debt, Current Entity Small Business Entity Small Business 4.50% senior notes due 2035 Senior Notes Due In 2035 At 4.50 Percent [Member] Senior Notes Due In 2035 At 4.50 Percent. Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Senior Notes Issued in 2024 Senior Notes Issued in 2024 [Member] Senior Notes Issued in 2024 Effective Income Tax Rate Reconciliation, Deduction, Percent Effective Income Tax Rate Reconciliation, Deduction, Percent 1.25% senior euro notes due 2031 (€650 principal) Senior Euro Notes Due in 2031 at 1.250 Percent [Member] Represents information pertaining to the 1.250% senior Euro note due in 2031. Document Transition Report Document Transition Report Summary of amounts and location of operating and finance leases on the consolidated balance sheets Operating and Finance Lease Balance Sheet Disclosure [Table Text Block] Operating and Finance Lease Balance Sheet Disclosure [Table Text Block] Operating Lease assets balance sheet caption Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Business Combination, Recognized Asset Acquired, Other Asset, Noncurrent Business Combination, Recognized Asset Acquired, Other Asset, Noncurrent Interest Expense, Net Interest Income (Expense), Operating and Nonoperating [Abstract] Qulipta Qulipta [Member] Qulipta AbbVie's share of development costs (included in R&D) Research And Development Expense From Collaborative Arrangements Amount of research and development expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms. Total lease payments Finance Lease, Liability, to be Paid Net change in commercial paper borrowings with original maturities of three months or less Proceeds from (Repayments of) Commercial Paper Underlying Securities Award Underlying Securities Amount Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, License agreements Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, License agreements Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, License agreements Equity Component [Domain] Equity Component [Domain] Document Period End Date Document Period End Date Income Taxes Income Tax Disclosure [Text Block] United Kingdom UNITED KINGDOM Payments of contingent consideration liabilities Payment for Contingent Consideration Liability, Financing Activities Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Debt securities Defined Benefit Plan, Debt Security [Member] Short-term lease cost Short-Term Lease, Cost Noncurrent operating lease liabilities balance sheet caption Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Restructuring costs location [Axis] Restructuring costs location [Axis] Restructuring costs location Total equity (deficit) Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Accruals and reserves Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Document Type Document Type Shares units outstanding at the beginning of the period (in shares) Shares units outstanding at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Level 3 Fair Value, Inputs, Level 3 [Member] Earnings Per Share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Loss Contingencies [Table] Loss Contingencies [Table] Product and Service [Axis] Product and Service [Axis] Spain SPAIN 4.875% senior notes due 2048 Senior Notes Due in 2048 At 4.875 Percent [Member] Senior Notes Due in 2048 At 4.875 Percent. Net revenues Revenue from Contract with Customer, Excluding Assessed Tax Variable lease cost Variable Lease, Cost Total current assets Assets, Current Research and Development Milestone Expenses Research and Development Milestone Expenses Research and Development Milestone Expenses Statistical Measurement [Axis] Statistical Measurement [Axis] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Aggregate intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value France FRANCE Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Duration of forward exchange contracts Derivative, Term of Contract Earnings available to common shareholders Net Income (Loss) Available to Common Stockholders, Basic Rinvoq RINVOQ [Member] Represents information pertaining to RINVOQ, a product of the entity. Entity Information [Line Items] Entity Information [Line Items] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Current liabilities Liabilities, Current [Abstract] Summary of pre-tax amounts and location of derivatives recognized in the consolidated statement of earnings Derivative Instruments, Gain (Loss) [Table Text Block] Cash per share received by shareholders (in dollars per share) Business Combination, Price Per Share Level 1 Fair Value, Inputs, Level 1 [Member] Revolving credit facility outstanding Long-Term Line of Credit Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Business Combination, Recognized Liability Assumed, Accounts Payable, Current Business Combination, Recognized Liability Assumed, Accounts Payable, Current Net operating losses and other carryforwards Net operating losses and other credit carryforwards Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss and other tax credit carryforwards. Diluted earnings per share (in dollars per share) Earnings Per Share, Diluted Accounts receivable, net AbbVie's receivable from Janssen Accounts Receivable, after Allowance for Credit Loss, Current Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] AOCI Attributable to Parent, Net of Tax AOCI Attributable to Parent, Net of Tax [Roll Forward] Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Resonic Resonic [Member] Resonic Share of collaboration development costs responsible by the entity (as a percent) Collaborative Arrangements Percentage Of Share Of Development Costs Represents the percentage of share in collaboration development costs responsible by the entity under cost sharing arrangement. Common stock held in treasury, at cost (in shares) Treasury Stock, Common, Shares Auditor Location Auditor Location Cash-Settled, Post-Closing Expense for Employee Incentive and Compensation Awards Cash-Settled, Post-Closing Expense for Employee Incentive and Compensation Awards Cash-Settled, Post-Closing Expense for Employee Incentive and Compensation Awards Key Product Portfolio [Domain] Key Product Portfolio [Domain] [Domain] for Information concerning the company's portfolios of key products. Gross margin Gross Profit Gilgamesh Pharmaceuticals, Inc. Gilgamesh Pharmaceuticals, Inc. [Member] Gilgamesh Pharmaceuticals, Inc. Excess tax benefits realized from stock-based compensation Excess tax benefits realized from stock-based compensation Excess tax benefits realized from stock-based compensation Other Long-Term Liabilities Liabilities, Other than Long-Term Debt, Noncurrent [Abstract] Schedule of weighted-average assumptions used in determining benefit obligations at the measurement date Schedule of Key Assumptions Used in Measurement of Defined Benefit Plan Benefit Obligation [Table Text Block] Tabular disclosure of the assumptions used to determine for pension plans and/or other employee benefit plans the benefit obligation, including assumed discount rates and rate increase in compensation increase. Actuarial (gain) loss Actuarial (gain) loss Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Principal U.S. Customers Principal U.S. Customers [Member] Principal U.S. Customers Less: Interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Income Taxes Paid, Net Income Taxes Paid, Net Stock Repurchase Program, Increase in Authorized Amount Stock Repurchase Program, Increase in Authorized Amount Stock Repurchase Program, Increase in Authorized Amount 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Two Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Unamortized deferred financing costs Long Term Debt And Capital Lease Obligations Debt Instrument Unamortized Financing Costs Represents the amount of deferred financing costs that was originally recognized at the issuance of the instrument that has yet to be amortized, as on the balance sheet date. Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Salaries, wages and commissions Employee-related Liabilities, Current Total lease payments Lessee, Operating Lease, Liability, to be Paid Total loss (gain) Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax Payments and other adjustments Restructuring Reserve Period Cash Settled and Other Adjustments The change in the restructuring reserve related to the amount of cash paid and other adjustments during the period. Expiration Date Trading Arrangement Expiration Date Amount excluded from the assessment of effectiveness for cash flow hedges Gain (Loss) from Components Excluded from Assessment of Cash Flow Hedge Effectiveness, Net 2030 Finite-Lived Intangible Asset, Expected Amortization, Year Five Non-U.S. government securities Debt Security, Government, Non-US [Member] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Geographic Risk Geographic Concentration Risk [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Accounts receivable Increase (Decrease) in Accounts Receivable Inventories Inventory, Policy [Policy Text Block] Restructuring Cost [Table] Restructuring Cost [Table] Entity Current Reporting Status Entity Current Reporting Status Nimble Therapeutics, Inc. Nimble Therapeutics, Inc. [Member] Nimble Therapeutics, Inc. Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Probability of payment for royalties by indication Probability of Payment for Royalties by Indication [Member] Represents probability of payment for royalties by indication. Japan JAPAN Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent Foreign currency translation adjustments Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Auditor Information [Abstract] Auditor Information [Abstract] Auditor Information U.S. Federal and State Domestic Tax Authority and State and Local Jurisdiction [Member] Represents information pertaining to the designated tax departments of domestic, state and local governments entitled to levy and collect income taxes from the entity. Adjustments to reconcile net earnings to net cash from operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Noncash Item [Abstract] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Executive Category: Executive Category [Axis] Foreign currency forward exchange contracts Foreign Exchange Forward [Member] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Other operating income Other Operating Income (Expense), Net Current finance lease liabilities Finance Lease, Liability, Current Accumulated benefit obligation Defined Benefit Plan, Accumulated Benefit Obligation Term Loan due April 2027 Term Loan due April 2027 [Member] Term Loan due April 2027 Interest expense Interest Expense, Operating and Nonoperating Proceeds from issuance of long-term debt Proceeds from Issuance of Long-Term Debt Current Fiscal Year End Date Current Fiscal Year End Date IRELAND IRELAND Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Weighted-average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Total lease assets Lease, Right-of-Use Asset Amount of lessee's right to use underlying asset under operating and finance leases. Sec 2.625 Senior Notes Due 2028 Sec 2.625 Senior Notes Due 2028 [Member] Sec 2.625 Senior Notes Due 2028 Collaborations Collaborative Arrangement Disclosure [Text Block] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Weighted-average grant-date fair value of the stock options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Amortization of prior service credit (cost) Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax Italy ITALY Number of principal customers Number of Principal US Customers Number of Principal US Customers Represents the number of principal U.S. customers of the entity. Summary of bases used to measure assets and liabilities carried at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Common stock received for each vested award (in shares) Share Based Compensation Arrangement by Share Based Payment Award Equity Instruments Other than Options Number of Shares to be Issued upon Vesting for Each Award Vested Represents the number of shares of common stock to be received by recipient upon vesting for each equity-based awards, excluding options, vested. Beginning balance Ending balance Unrecognized Tax Benefits Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) Repayments of Other Short-Term Debt Repayments of Other Short-Term Debt Repayments of Other Short-Term Debt Acquired IPR&D and milestones Upfront Costs Related To Collaborations Represents the amount of upfront costs related to collaborations reported in the statement of cash flows. Reconciliation of the fair value measurements that use significant unobservable inputs (Level 3) Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Vraylar Vraylar [Member] Represents information pertaining to Vraylar, a product of the entity. Accounts payable and accrued liabilities Accounts payable and accrued liabilities AbbVie's payable to Janssen Accounts Payable and Accrued Liabilities, Current 2027 Long-Term Debt, Maturity, Year Two Leases Lessee, Operating Leases [Text Block] Cash flows from financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Measure: Measure [Axis] PUERTO RICO PUERTO RICO Net investment hedging activities AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent [Member] Property Plant And Equipment Type [Domain] Long-Lived Tangible Asset [Domain] Remaining share repurchase authorization amount Share Repurchase Program, Remaining Authorized, Amount Cost of products sold Losses (gains) on foreign currency exchange contracts Cost of Product and Service Sold Schedule of the impact of significant amounts reclassified out of each component of accumulated other comprehensive loss Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Entity Tax Identification Number Entity Tax Identification Number Effective Income Tax Rate Reconciliation, Tax Credit, Percent Effective Income Tax Rate Reconciliation, Tax Credit, Percent Outstanding at the beginning of the period (in dollars per share) Outstanding at the end of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Cash flow hedging activities Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] December 2023 Term Loan Credit Agreement December 2023 Term Loan Credit Agreement [Member] December 2023 Term Loan Credit Agreement Common stock, issued (in shares) Common Stock, Shares, Issued Pfizer License Agreement Pfizer License Agreement [Member] Pfizer License Agreement 2029 Long-Term Debt, Maturity, Year Four Weighted-average remaining lease term for operating leases Operating Lease, Weighted Average Remaining Lease Term Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Dividends payable Dividends Payable, Current Entity Public Float Entity Public Float Summary of changes in the carrying amount of goodwill Schedule of Goodwill [Table Text Block] Trading Arrangement: Trading Arrangement [Axis] Total Shareholder Return Amount Total Shareholder Return Amount Transfers of assets between the fair value measurement levels Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net [Abstract] Legal Proceedings and Contingencies Loss Contingencies [Line Items] Actuarial loss, net Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax Change in fair value recognized in net earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Security Exchange Name Security Exchange Name Income Tax Paid, Foreign, after Refund Received Income Tax Paid, Foreign, after Refund Received Effective Income Tax Rate Reconciliation, Cross-Border, Other, Percent Effective Income Tax Rate Reconciliation, Cross-Border, Other, Percent Senior notes due 2035 at 5.20% Senior notes due 2035 at 5.20% [Member] Senior notes due 2035 at 5.20% Accumulated goodwill impairment losses Goodwill, Impaired, Accumulated Impairment Loss [Abstract] Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount Performance period Share-based Compensation Arrangement by Share-based Payment Award, Performance Period Share-based Compensation Arrangement by Share-based Payment Award, Performance Period Revolving credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Venclexta VENCLEXTA [Member] Represents information pertaining to VENCLEXTA, a product of the entity. Pension and other post-employment benefits Other long-term liabilities Liability, Defined Benefit Plan, Noncurrent Total Lease Liabiltiies, Payments, Due [Abstract] Lease Liabilities, Payments, Due Statement [Line Items] Statement [Line Items] Summary of cash activity in the restructuring reserve Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Product Liability ALCL Litigation in Other Countries Product Liability ALCL Litigation in Other Countries [Member] Product Liability ALCL Litigation in Other Countries Cash and equivalents Cash and Cash Equivalent Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Aiada Therapeutics Aiada Therapeutics [Member] Aiada Therapeutics Common stock Common Stock [Member] Forfeited (in dollars per share) Share Based Compensation Arrangement by Share Based Payment Award Equity Instruments Other than Options Expired Weighted Average Grant Date Fair Value Represents the weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that expired during the period. Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period MALTA MALTA Finance leases Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Net change in cash and equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Lapsed and forfeited (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations and Forfeitures in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations and Forfeitures in Period, Weighted Average Exercise Price Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Statistical Measurement [Domain] Statistical Measurement [Domain] Business Combination, Recognized Asset Acquired, Property, Plant, and Equipment Business Combination, Recognized Asset Acquired, Property, Plant, and Equipment Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Current operating lease liabilities balance sheet caption Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Foreign Plan [Member] Foreign Plan [Member] 2.95% senior notes due 2026 Senior Notes Due in 2026 At 2.95 Percent [Member] Senior Notes Due in 2026 At 2.95 Percent Short-term borrowings Short-term borrowings Short-Term Debt, Fair Value Weighted-average effective interest rate Long-Term Debt, Weighted Average Interest Rate, at Point in Time Total intangible assets gross carrying amount Intangible Assets, Gross (Excluding Goodwill) Other assets Other Noncurrent Assets [Member] Interest rate swap contracts Interest Rate Swap [Member] 3.20% senior notes due 2029 Senior Notes Due in 2029 At 3.20 Percent [Member] Senior Notes Due in 2029 At 3.20 Percent Leases [Abstract] Leases [Abstract] Increase due to prior year tax positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Schedule of other long-term liabilities Other Noncurrent Liabilities [Table Text Block] Type of Restructuring [Domain] Type of Restructuring [Domain] Interest expense, net Interest expense, net Gain on derivative amount excluded from effectiveness testing Interest Income (Expense), Nonoperating Retirement Plan Name [Axis] Retirement Plan Name [Axis] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Basic earnings per share (in dollars per share) Earnings Per Share, Basic Pre-tax gains (losses) from net investment hedges recognized in other comprehensive income Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Commercial Paper Commercial Paper [Member] Accounts payable and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Liabilities Liabilities, Fair Value Disclosure [Abstract] Schedule of profit and cost sharing relationship Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Fair value of plan assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets Effective Income Tax Rate Reconciliation, Tax Contingency, Percent Effective Income Tax Rate Reconciliation, Tax Contingency, Percent Total deferred tax assets Deferred Tax Assets, Gross Discount rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Discount rate Measurement Input, Discount Rate [Member] Other comprehensive income (loss) Other comprehensive loss, net of tax Other Comprehensive Income (Loss), Net of Tax Short-term borrowings Short-Term Debt Measurement Input Type [Domain] Measurement Input Type [Domain] Collaboration revenues Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 2028 Finance Lease, Liability, to be Paid, Year Three Compensation and employee benefits Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits Indefinite-Lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Category of Item Purchased [Axis] Category of Item Purchased [Axis] Amortization of Inventory Step up Amortization of Inventory Step up Amortization of Inventory Step up Foreign currency translation adjustments, tax expense (benefit) Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Gain (loss) on derivatives Derivative Instruments, Gain (Loss) [Line Items] Pre-tax compensation expense Share-Based Payment Arrangement, Expense Hedging Designation [Domain] Hedging Designation [Domain] Current finance lease liabilities balance sheet caption Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Current assets Assets, Current [Abstract] Fair Value Measurement Inputs and Valuation Techniques [Abstract] Total liabilities and equity Liabilities and Equity Foreign Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Schedule of weighted-average remaining lease term and weighted-average discount rate for operating and finance leases Operating and Finance Lease Weighted-Average Remaining Lease Term and Discount Rate [Table Text Block] Operating and Finance Lease Weighted-Average Remaining Lease Term and Discount Rate [Table Text Block] License agreements Licensing Agreements [Member] Significant amounts reclassified out of each component of AOCI Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Other Deferred Tax Assets, Other After-tax compensation expense Share-Based Payment Arrangement, Expense, after Tax Term Loan Due May 2025 Term Loan Due May 2025 [Member] Term Loan Due May 2025 Accounting Policies [Abstract] Accounting Policies [Abstract] Revolving credit facility term Line of Credit Facility, Expiration Period Summary of future maturities of AbbVie's operating lease liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Non-current Financing Liability, Change in Fair Value Non-current Financing Liability, Change in Fair Value Non-current Financing Liability, Change in Fair Value Other acquisitions and investments, net of cash acquired Payments to Acquire Other Investments Treasury Stock, Common Treasury Stock, Common [Member] Fair market value of awards vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Pay vs Performance Disclosure [Line Items] Present value of lease liabilities Operating Lease, Liability U.S. tax impact of branch accounting, net of FTC Effective Income Tax Rate Reconciliation, U.S. tax impact of branch accounting, net of FTC, Amount Effective Income Tax Rate Reconciliation, U.S. tax impact of branch accounting, net of FTC, Amount Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration] Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration] Liabilities Liabilities [Abstract] Long-Term Debt, Weighted Average Interest Rate, over Time Long-Term Debt, Weighted Average Interest Rate, over Time Other long-term liabilities Other long-term liabilities Other Liabilities, Noncurrent Aggregate intrinsic value Share Based Compensation Arrangement by Share Based Payment Award Aggregate Intrinsic Value [Abstract] Imbruvica Imbruvica [Member] Represents information pertaining to Imbruvica, a product of the entity. Ultimate per capita trend rate for health care costs from 2030 and thereafter (as a percent) Defined Benefit Plan Ultimate Health Care Cost Trend Rate Assumed to Decrease The ultimate trend rate for health care costs assumed to decrease. Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Company Selected Measure Amount Company Selected Measure Amount Company contributions Defined Benefit Plan, Plan Assets, Contributions by Employer 2028 Lessee, Operating Lease, Liability, to be Paid, Year Three Debt Issuance Costs, Gross Debt Issuance Costs, Gross Comprehensive income attributable to AbbVie Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Measurement Input Type [Axis] Measurement Input Type [Axis] Name Measure Name Schedule of earnings before income tax expense Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Resonic and Durysta Resonic and Durysta [Member] Resonic and Durysta Summary of changes in fair value of Level 3 inputs Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Deferred income taxes Deferred Income Tax Liabilities, Net Expected long-term rate of return on plan assets Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets Number of individual plaintiff lawsuits Loss Contingency Individual Plaintiff Lawsuits Number Represents the number of individual plaintiff lawsuits filed, pertaining to a loss contingency during the period. Long-term debt obligations, gross Long-Term Debt Total assets Assets Cash flows from investing activities Cash Provided by (Used in) Investing Activity, Continuing Operation [Abstract] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year One Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Geographical [Domain] Geographical [Domain] Income Taxes Income Tax, Policy [Policy Text Block] Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Allergan integration plan Allergan Integration Plan [Member] Represents information pertaining to the Allergan integration plan. Concentration Risk Type [Axis] Concentration Risk Type [Axis] 4.85% senior notes due 2044 Senior Notes Due 2044 at 4.850 [Member] Senior Notes Due 2044 at 4.850 Cerevel Therapeutics Cerevel Therapeutics [Member] Cerevel Therapeutics Assets Assets, Fair Value Disclosure [Abstract] Borrowings (repayments) of long-term debt Proceeds from (Repayments of) Long-Term Debt and Capital Securities 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Four Research and development Research and Development Expense (Excluding Acquired in Process Cost) Cash dividends declared per common share (in dollars per share) Common Stock, Dividends, Per Share, Declared Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Level 2 Fair Value, Inputs, Level 2 [Member] Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Business Combination [Domain] Business Combination [Domain] Operating leases Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Retirement-eligible employees' age Share Based Compensation Arrangement By Share Based Payment Award Retirement Eligible Age Represents retirement eligible employees' age. Fair value of plan assets Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Schedule of income tax expense Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] PEO PEO [Member] Product Liability ALCL Litigation Product Liability ALCL Litigation [Member] Product Liability ALCL Litigation Transfers of assets into Level 3 of the fair value hierarchy Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 Number of claims pending Loss Contingency, Pending Claims, Number Effective Income Tax Rate Reconciliation, GILTI, Amount Effective Income Tax Rate Reconciliation, GILTI, Amount Employee Severance Employee Severance [Member] Sales and maturities of investment securities Proceeds from Sale, Maturity and Collection of Investments Sec 2.125 Senior Notes due 2028 Sec 2.125 Senior Notes due 2028 [Member] Sec 2.125 Senior Notes due 2028 [Member] Supplemental schedule of non-cash investing and financing activities Noncash Investing and Financing Items [Abstract] Excess of book basis over tax basis of intangible assets Deferred Tax Liabilities, Intangible Assets Income Tax Paid, by Individual Jurisdiction [Line Items] Income Tax Paid, by Individual Jurisdiction [Line Items] Total lease liabilities Present value of lease liabilities Lease, Liability Present value of lessee's discounted obligation for lease payments from operating and finance leases. United States UNITED STATES Changes in operating assets and liabilities, net of acquisitions: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Neuroscience Neuroscience [Member] Represents information pertaining to Neuroscience, a key product portfolio of the entity. Retained earnings (accumulated deficit) Retained Earnings [Member] Income Tax Jurisdiction [Axis] Income Tax Jurisdiction [Axis] Schedule of fourth quarter financial results Quarterly Financial Information [Table Text Block] Cash and equivalents, beginning of year Cash and equivalents, end of year Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement [Abstract] Income Statement [Abstract] Capstan Therapeutics, Inc. Capstan Therapeutics, Inc. [Member] Capstan Therapeutics, Inc. Purchases of investment securities Payments to Acquire Marketable Securities Other Aesthetics Other Aesthetics [Member] Represents information pertaining to Other Aesthetics products. Interest expense, net Interest Expense [Member] Niaspan Niaspan [Member] Represents information pertaining to Niaspan, a product of the entity. Lapsed and forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations and Forfeitures in Period Money market funds and time deposits Investments, Fair Value Disclosure Repayments of long-term debt and finance lease obligations Repayment of Long-Term Debt, Long-Term Lease Obligation, and Capital Security Intangible assets, net Total intangible assets, net Intangible Assets, Net (Excluding Goodwill) Product and Service [Domain] Product and Service [Domain] Fair value hedges, unamortized bond premiums/discounts, deferred financing costs, finance lease obligations and financing liability Long Term Debt And Capital Lease Obligations Fair Value Hedges Unamortized Bond Premiums and Discounts Deferred Financing Costs And Finance Lease Obligations Represents the total amount of fair value hedges, unamortized bond premiums and discounts, deferred financing costs and finance lease obligations related to long term debt and finance lease obligations. Transfers of liabilities out of Level 3 of the fair value hierarchy Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 4.625% senior notes due 2042 Senior Notes Due 2042 at 4.625 Percent [Member] Senior Notes Due 2042 at 4.625 Percent Net earnings Net earnings Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Total liabilities Liabilities, Fair Value Disclosure Business Combination [Table] Business Combination [Table] Notional amount of derivative instruments Derivative, Notional Amount Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] 2.125% senior euro notes due 2029 (€550 principal) Senior Euro Notes Due 2029 At 2.125 Percent [Member] Senior Euro Notes Due 2029 At 2.125 Percent Income Tax Paid, by Individual Jurisdiction [Table] Income Tax Paid, by Individual Jurisdiction [Table] Business Combination, Recognized Asset Acquired and Liability Assumed Business Combination, Recognized Asset Acquired and Liability Assumed [Table Text Block] 0.75% senior euro notes due 2027 (€750 principal) Senior Euro Notes Due in 2027 at 0.750 Percent [Member] Represents information pertaining to the 0.750% senior Euro note due in 2027. Alphagan/Combigan Alphagan/Combigan [Member] Represents information pertaining to Alphagan/Combigan, a product of the entity. City Area Code City Area Code Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Other Neuroscience Other Neuroscience [Member] Represents information pertaining to Other Neuroscience products. Debt, Credit Facilities, and Commitments and Contingencies Debt, Credit Facilities and Commitments and Contingencies Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Total long-lived assets Long-Lived Assets Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] 5.35% senior notes due 2044 Senior Notes 5.35 Percent Due 2044 [Member] Senior Notes 5.35 Percent Due 2044 Fair value hedges Fair Value Hedging [Member] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assumed In Process Research and Development Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assumed In Process Research and Development Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assumed In Process Research and Development Other Oncology Other Oncology [Member] Other Oncology Change in noncontrolling interest Noncontrolling Interest, Period Increase (Decrease) Amortization of actuarial loss Defined Benefit Plan, Amortization of Gain (Loss) Effective Income Tax Rate Reconciliation [Line Items] Effective Income Tax Rate Reconciliation [Line Items] Total lease cost Lease, Cost Selling, general and administrative Selling, General and Administrative Expenses [Member] Cash balance interest crediting rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate Equity securities Equity Securities, FV-NI Cash flow hedges Cash Flow Hedging [Member] Cost of products sold Cost of products sold Cost of Sales [Member] Goodwill Balance at the beginning of the period Balance at the end of the period Goodwill 2.125% senior euro notes due 2028 (€750 principal) Senior Euro Notes 2.125 Percent Due 2028 [Member] Senior Euro Notes 2.125 Percent Due 2028 [Member] Summary of lease costs recognized in the condensed consolidated statements of earnings Lease, Cost [Table Text Block] Prepaid expenses and other Prepaid Expenses and Other Current Assets [Member] Fair value of plan assets Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets Domestic Deferred Federal Income Tax Expense (Benefit) Transfers of assets out of Level 3 of the fair value hierarchy Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 International Non-US [Member] Unrecognized Tax Benefits Unrecognized Tax Benefits [Roll Forward] Auditor Name Auditor Name Concentration Risk [Table] Concentration Risk [Table] Equipment Equipment [Member] Business Combination, Recognized Asset Acquired, Inventory, Current Business Combination, Recognized Asset Acquired, Inventory, Current All other All Other Countries [Member] All Other Countries [Member] Other supplemental information Supplemental Cash Flow Information [Abstract] Business Combination, Recognized Asset Acquired, Receivable, Current Business Combination, Recognized Asset Acquired, Receivable, Current Other Key Products Other Key Products [Member] Represents information pertaining to other key products of the entity. Restructuring charges Restructuring Cost and Reserve [Line Items] Accumulated goodwill impairment losses Goodwill, Impaired, Accumulated Impairment Loss Other Performance Measure, Amount Other Performance Measure, Amount Weighted- average exercise price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] U.S. government securities US Treasury and Government [Member] Foreign currency translation adjustments, net of tax expense (benefit) of $63 in 2025, $(39) in 2024 and $15 in 2023 Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Pension and Other Post-Employment Benefits Pension and Other Postretirement Plans, Policy [Policy Text Block] Licensing, Acquisitions, and Other Arrangements Licensing, Acquisitions, and Other Arrangements Derivative Instrument [Axis] Derivative Instrument [Axis] Benefits paid Defined Benefit Plan, Plan Assets, Benefits Paid Effective Income Tax Rate Reconciliation, Deduction, Amount Effective Income Tax Rate Reconciliation, Deduction, Amount Leases Lessee, Finance Leases [Text Block] Schedule of benefit plan information Schedule of Accumulated and Projected Benefit Obligations [Table Text Block] 2026 Lease, Liability, Payments, Due Next Rolling Twelve Months Amount of lessee's undiscounted obligation for lease payments for operating and finance leases, due in next rolling twelve months following latest statement of financial position date. Additional paid-in capital Additional Paid in Capital, Common Stock Cash flows from investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Interest paid, net of portion capitalized Interest Paid, Excluding Capitalized Interest, Operating Activity Document Fiscal Year Focus Document Fiscal Year Focus Thereafter Lease, Liability, Payments, Due after Year Five Amount of lessee's undiscounted obligation for lease payments for operating and finance leases, due after fifth fiscal year following latest fiscal year. Operating lease assets Operating Lease, Right-of-Use Asset Product Liability Other Litigation in State Court Product Liability Other Litigation in State Court [Member] Product Liability Other Litigation in State Court Fair value hedges Long Term Debt and Capital Lease Obligations Fair Value Hedges, Net Represents the amount of net fair value hedging, as on the balance sheet date. Effective tax rate Effective Income Tax Rate Reconciliation, Percent Effective Income Tax Rate Reconciliation, Percent Decrease due to prior year tax positions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Operating lease cost Operating Lease, Cost Cash flows from operating activities Cash Provided by (Used in) Operating Activity, Continuing Operation [Abstract] Book value Reported Value Measurement [Member] Business Combination, Acquisition-Related Cost, Expense Business Combination, Acquisition-Related Cost, Expense Period for recognition of unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Legal Proceedings and Contingencies Legal Matters and Contingencies [Text Block] Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Valuation allowances Deferred Tax Assets, Valuation Allowance Equity [Abstract] Equity [Abstract] Estimated Litigation Liability Estimated Litigation Liability Goodwill and Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] International Defined Benefit Plan, Equity Securities, Non-US [Member] Buildings Building [Member] Derivatives Derivatives, Policy [Policy Text Block] Segment and Geographic Area Information Segment Reporting Disclosure [Text Block] Fair value, asset and liability measures Bases used to measure the approximate fair values of the financial instruments Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Not designated as hedging instrument Not Designated as Hedging Instrument [Member] Beginning of period End of period Fair value of plan assets Defined Benefit Plan, Plan Assets, Amount Domestic Current Federal Tax Expense (Benefit) Total long-term debt and finance lease obligations Aggregate principal amount outstanding Debt and Lease Obligation Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Definite-lived intangible assets Finite-Lived Intangible Assets [Line Items] Transfers of liabilities into Level 3 of the fair value hierarchy Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 Summary of net periodic benefit cost relating to the company's defined benefit and other post-employment plans Schedule of Net Benefit Costs [Table Text Block] Other fixed income securities Other Debt Obligations [Member] Business Combination, Recognized Liability Assumed, Other Liability, Noncurrent Business Combination, Recognized Liability Assumed, Other Liability, Noncurrent Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Contingent consideration Business Combination, Contingent Consideration, Liability Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Weighted Average Weighted Average [Member] Leases Lessee, Leases [Policy Text Block] Amortization of intangible assets Amortization of Intangible Assets Selling, general and administrative Selling, General and Administrative Expense Exchange [Domain] Exchange [Domain] Summary of changes in each component of accumulated other comprehensive loss, net of tax Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] ImmunoGen Senior Secured Term Loan ImmunoGen Senior Secured Term Loan [Member] ImmunoGen Senior Secured Term Loan Royalty and license arrangements Accrued Royalties, Current Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Financing liability Noncurrent, Financing Liability Noncurrent, Financing Liability Revolving credit facility Revolving Credit Facility [Member] Accounts Receivable Accounts Receivable [Policy Text Block] Skyrizi SKYRIZI [Member] Represents information pertaining to SKYRIZI, a product of the entity. Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) Selling, General And Administrative Expense From Collaborative Arrangements Amount of selling, general and administrative expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms. Present value of lease liabilities Finance Lease, Liability Arrangement Duration Trading Arrangement Duration Business Combination, Acquiree's Earnings (Loss) since Acquisition Date, Actual Business Combination, Acquiree's Earnings (Loss) since Acquisition Date, Actual Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Debt issuance costs Payment of Financing and Stock Issuance Costs Ichnos Glenmark Innovation, Inc. Ichnos Glenmark Innovation, Inc. [Member] Ichnos Glenmark Innovation, Inc. Local Phone Number Local Phone Number Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Arrangements And Nonarrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Europe Europe [Member] Other, net Payment for (Proceeds from) Other Investing Activity Thereafter Long-Term Debt, Maturity, after Year Five Equity Share-Based Payment Arrangement [Text Block] Business Combination, Recognized Asset Acquired, Cash and Cash Equivalent Business Combination, Recognized Asset Acquired, Cash and Cash Equivalent Effective Income Tax Rate Reconciliation, Net Operating Loss Utilization, Amount Effective Income Tax Rate Reconciliation, Net Operating Loss Utilization, Amount Effective Income Tax Rate Reconciliation, Net Operating Loss Utilization, Amount Assets Assets [Abstract] Credit Facility [Axis] Credit Facility [Axis] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Debt Instrument [Axis] Debt Instrument [Axis] Weighted-average remaining life (in years) Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract] Business Combination Business Combination [Line Items] Performance-vested RSUs Performance-based Restricted Stock Units [Member] Performance-based Restricted Stock Units [Member] Credit Facility [Domain] Credit Facility [Domain] Stockholders' equity (deficit) Equity, Attributable to Parent [Abstract] Proceeds from Short-Term Debt Proceeds from Short-Term Debt Purchases of treasury stock Payment for shares repurchased Treasury Stock, Value, Acquired, Cost Method Business Combination, Recognized Asset Acquired, Asset, Noncurrent Business Combination, Recognized Asset Acquired, Asset, Noncurrent Stated interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Noncurrent operating lease liabilities Operating Lease, Liability, Noncurrent Entity Voluntary Filers Entity Voluntary Filers Milestone payments Collaborative Arrangement Milestone Method Payments Receivable The maximum milestone payments that may be received by the entity based on the achievement of specified events under a collaborative arrangement. Fair value - Derivatives in asset position Derivative Asset, Subject to Master Netting Arrangement, before Offset Derivative Asset, Subject to Master Netting Arrangement, before Offset Entry Registrant Name Entity Registrant Name Collaborative arrangement Collaborative Arrangement [Member] Retirement Plan Name [Domain] Retirement Plan Name [Domain] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Net periodic benefit cost (credit) Defined Benefit Plan, Net Periodic Benefit Cost (Credit) 2026 Lessee, Operating Lease, Liability, to be Paid, Next Rolling 12 Months Treasury rate lock agreements Treasury Lock [Member] Other, primarily foreign currency translation adjustments Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) NEW YORK STOCK EXCHANGE, INC. NEW YORK STOCK EXCHANGE, INC. [Member] Global - AbbVie's share of other costs (included in respective line items) Cost Sharing Expenses Represents cost sharing expenses. Net investment hedging activities, net of tax expense (benefit) of $(266) in 2025, $133 in 2024 and $(109) in 2023 Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), After Reclassification and Tax Amount, after tax and reclassification, of gain (loss) from derivative instruments and nonderivative instruments designated and qualifying as net investment hedge. Income tax assets and liabilities, net Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable 4.25% senior notes due 2049 Senior Notes Due in 2049 At 4.25 Percent [Member] Senior Notes Due in 2049 At 4.25 Percent Total assets Assets, Fair Value Disclosure Maximum future payments upon achievement of certain milestones Additional Contribution To Acquire In Process Research And Development Collaborations Represents the maximum additional payment for research and early development of collaboration projects. U.S. Federal and Non-U.S. Domestic and Foreign Tax Authority [Member] Designated tax department of the government that is entitled to levy and collect income taxes from the entity inside and outside its country of domicile. Carrying amount of investments in equity securities that do not have readily determinable fair values Equity Securities without Readily Determinable Fair Value, Amount Number of Operating Segments Number of Operating Segments 2.5% Convertible Senior Note 2.5% Convertible Senior Note [Member] 2.5% Convertible Senior Note Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) Cost of Goods And Services Sold From Collaborative Arrangements Amount of costs of goods and services sold arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms. Tax Credit Carryforward Tax Credit Carryforward [Line Items] Juvederm Collection Juvederm Collection [Member] Represents information pertaining to Juvederm Collection, a product of the entity. Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Interest cost Defined Benefit Plan, Interest Cost Amortization period of differences between the expected and actual return on plan assets Amortization Period of Differences between the Expected Long Term Return on Plan Assets and the Actual Return Represents the period over which differences between the expected long-term return on plan assets and the actual return will be amortized. Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule of definite-lived intangible assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Stock-based compensation plans and other Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Foreign Deferred Foreign Income Tax Expense (Benefit) Accounts receivable, net Accounts Receivable [Member] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Summary of charges associated with integration plan Restructuring and Related Costs [Table Text Block] Other, net Proceeds from (Payment for) Other Financing Activity Net losses (gains) reclassified from accumulated other comprehensive loss Total reclassifications, net of tax Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Name Trading Arrangement, Individual Name Schedule of Short-term Debt [Table] Short-Term Debt [Table] Prescription Drug Abuse Litigation brought by States, Counties, Cities and other Municipal Entities Prescription Drug Abuse Litigation brought by States, Counties, Cities and other Municipal Entities [Member] Prescription Drug Abuse Litigation brought by States, Counties, Cities and other Municipal Entities Aggregate principal amount of debt Aggregate principal amount of senior Euro notes Debt Instrument, Face Amount Pension and post-employment benefits, tax expense (benefit) Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Schedule of supplementary cash flow information regarding the company's leases Operating Lease Cash Flow Disclosure [Table Text Block] Operating Lease Cash Flow Disclosure [Table Text Block] Share Repurchase Program [Axis] Share Repurchase Program [Axis] All other Other Products [Member] Represents information pertaining to other products of the entity not specified anywhere. Name Awards Close in Time to MNPI Disclosures, Individual Name Amount excluded from the assessment of effectiveness for fair value hedges Gain (Loss) from Components Excluded from Assessment of Fair Value Hedge Effectiveness, Net Restructuring Type [Axis] Restructuring Type [Axis] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Supplemental Financial Information Supplemental Financial Information Proceeds from Other Short-Term Debt Proceeds from Other Short-Term Debt Other Other Accrued Liabilities, Noncurrent Common stock held in treasury, at cost, 70,802,593 shares as of December 31, 2025 and 66,337,508 as of December 31, 2024 Treasury Stock, Value Summary of future maturities of AbbVie's finance lease liabilities Finance Lease, Liability, to be Paid, Maturity [Table Text Block] December 2023 Bridge Credit Facility December 2023 Bridge Credit Facility [Member] December 2023 Bridge Credit Facility Litigation Case [Axis] Litigation Case [Axis] Accumulated other comprehensive income (loss) AOCI Including Portion Attributable to Noncontrolling Interest [Member] Minimum number of years of services Share Based Compensation Arrangement By Share Based Payment Award Retirement Eligible Employees Number Of Years Of Services Represents the minimum of number of years of services that employees have to work for the company in order to be eligible to retire with benefits. Auditor Firm ID Auditor Firm ID Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Axis] Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Gubra A/S Gubra A/S [Member] Gubra A/S Projected benefit obligation Beginning of period End of period Defined Benefit Plan, Benefit Obligation Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Excess of book basis over tax basis in investments Deferred Tax Liabilities, Investments Statement of Financial Position Location, Balance [Domain] Statement of Financial Position Location, Balance [Domain] Inventories Increase (Decrease) in Inventories Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Revenue Recognition Revenue [Policy Text Block] Senior notes Senior Notes [Member] 4.55% senior notes due 2035 Senior Notes Due 2035 at 4.550 Percent [Member] Senior Notes Due 2035 at 4.550 Percent All Executive Categories All Executive Categories [Member] Schedule of deferred tax assets and liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Information For Pension Plans With A Projected Benefit Obligation In Excess Of Plan Assets Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block] 4.75% senior notes due 2045 Senior Notes Due 2045 at 4.750 Percent [Member] Senior Notes Due 2045 at 4.750 Percent Finished goods Inventory, Finished Goods, Net of Reserves Finance lease assets Finance Lease, Right-of-Use Asset, after Accumulated Amortization Short-term investments Short-Term Investments 5.05% senior notes due 2034 Senior Notes 5.05 Percent Due 2034 [Member] Senior Notes 5.05 Percent Due 2034 Linzess/Constella Linzess/Constella [Member] Represents information pertaining to Linzess/Constella, a product of the entity. Commitments and contingencies Commitments and Contingencies Current portion of long-term debt and finance lease obligations, excluding fair value hedges Long Term Debt and Capital Lease Obligations Current Fair Value Disclosure Represents the fair value amount of obligation related to long-term debt (excluding convertible debt) and capital leases, the portion which is due in one year or less in the future. Pre Sixty Five Years of Age Pre Sixty Five Years Of Age [Member] Represents the health care cost trend rate for employees below 65 years age. FDA Approval FDA Approval [Member] FDA Approval Intangible assets - Developed product rights Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Finite-Lived Total assets measured at NAV Fair Value Measured at Net Asset Value Per Share [Member] Business Combination [Axis] Business Combination [Axis] Comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Term loan facilities Loans Payable [Member] Other Long-Term Debt Other Long-Term Debt Epkinly Epkinly [Member] Epkinly Noncontrolling interest Noncontrolling Interest [Member] Interest rate swap contracts Interest Rate Derivative Liabilities, at Fair Value Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Developed Product Rights Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Developed Product Rights Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Developed Product Rights Concentration of Risk Concentration Risk [Line Items] Short-term borrowings Short-Term Debt [Line Items] Schedule of long-lived assets by geographic area Long-Lived Assets by Geographic Areas [Table Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Option fees and exercise payments Option fees and exercise payments Option fees and exercise payments Tax audits, settlements and reserves Effective Income Tax Rate Reconciliation, Tax Settlement, Percent Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Number of outstanding derivative instruments containing credit risk contingent features Number of Credit Risk Derivatives Held Hedging Designation [Axis] Hedging Designation [Axis] U.S. Federal, State and Non-U.S. Domestic Tax Authority, State and Local Jurisdiction and Foreign Tax Authority [Member] Relates to information pertaining to designated tax departments of governments entitled to levy and collect income taxes from the entity inside and outside the entity's country of domicile, in addition to information pertaining to designated tax departments of a state or local government entitled to levy and collect income taxes from the entity. Deferred tax liabilities Deferred tax liabilities Business Combination, Recognized Liability Assumed, Deferred Tax Liability Schedule of Unrecognized Tax Benefits Roll Forward Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Senior notes due in 2028 4.65% Senior notes due in 2028 4.65 pecent [Member] Senior notes due in 2028 4.65 pecent Projected benefit obligation Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation Pension and post-employment benefits, net of tax expense (benefit) of $98 in 2025, $206 in 2024 and $(6) in 2023 Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Net investment hedges Net Investment Hedging [Member] Derivative Contract [Domain] Derivative Contract [Domain] RSUs and performance shares Restricted Stock Units And Performance Shares [Member] Restricted Stock Units And Performance Shares [Member] 2030 Defined Benefit Plan, Expected Future Benefit Payment, Year Five All Individuals All Individuals [Member] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] United States United States And Puerto Rico [Member] Represents information pertaining to United States and Puerto Rico. Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Acquisitions of property and equipment Payments to Acquire Property, Plant, and Equipment Name Forgone Recovery, Individual Name Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Payable on Funding Agreement Payable on Funding Agreement Payable on Funding Agreement Reclassification out of accumulated other comprehensive loss Reclassification out of Accumulated Other Comprehensive Income [Member] 4.80% senior notes due 2029 Senior Notes 4.80 Percent Due 2029 [Member] Senior Notes 4.80 Percent Due 2029 Exercise price for awards granted as percentage of market value on the date of grant Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Foreign currency translation adjustments and other Goodwill, Foreign Currency Translation, Gain (Loss) 364 day Term Loan Credit Agreement 364 day Term Loan Credit Agreement [Member] 364 day Term Loan Credit Agreement Equity securities Defined Benefit Plan, Equity Securities [Member] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Intangible Asset, Finite-Lived [Table] Intangible Asset, Finite-Lived [Table] Geographical [Axis] Geographical [Axis] Less: Interest Lease, Liability, Undiscounted Excess Amount Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating and finance leases. Stock-based compensation Effective Income Tax Rate Reconciliation Impacts Related to Stock Based Compensation Effective income tax rate impacts related to U.S. tax reform Fourth Quarter Financial Results (unaudited) Quarterly Financial Information [Text Block] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Business Combination, Pro Forma Information, Pro Forma Revenue Business Combination, Pro Forma Information, Pro Forma Revenue Net foreign exchange loss Gain (Loss), Foreign Currency Transaction, before Tax Gain (Loss), Foreign Currency Transaction, before Tax Cross-Currency Swap Contracts Cross-Currency Swap Contracts [Member] Cross-Currency Swap Contracts Remgen Co Remgen Co [Member] Remgen Co Earnings allocated to participating securities Participating Securities, Distributed and Undistributed Earnings (Loss), Basic Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration] Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration] Title of 12(b) Security Title of 12(b) Security Effective Income Tax Rate Reconciliation, GILTI, Percent Effective Income Tax Rate Reconciliation, GILTI, Percent Other Eye Care Other Eye Care [Member] Represents information pertaining to Other Eye Care products. Botox Cosmetic Botox Cosmetic [Member] Represents information pertaining to Botox Cosmetic, a product of the entity. Long-term Debt, Fiscal Year Maturity [Abstract] Long-Term Debt, Fiscal Year Maturity [Abstract] Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount Per share data Earnings Per Share [Abstract] U.S. tax credits Effective Income Tax Rate Reconciliation Us Tax Credits Represents the portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to accrual of U.S. tax credits under enacted tax laws. 2030 Lessee, Operating Lease, Liability, to be Paid, Year Five Restructuring Plan [Axis] Restructuring Plan [Axis] Licensing, Acquisitions, and Other Arrangements Acquisitions Collaborations and Other Arrangements Disclosure [Text Block] The entire disclosure for acquisitions, collaborations and other arrangements of the entity. Key Product Portfolio [Axis] Key Product Portfolio [Axis] Information concerning the company's portfolios of key products. Sec 1.250 Senior Notes Due 2031 Sec 1.250 Senior Notes Due 2031 [Member] Sec 1.250 Senior Notes Due 2031 4.80% senior notes due 2027 Senior Notes 4.80 Percent Due 2027 [Member] Senior Notes 4.80 Percent Due 2027 Tax credit carryforwards Tax Credit Carryforward, Amount Schedule of interest expense, net Interest Income and Interest Expense Disclosure [Table Text Block] Quarterly Financial Information Disclosure [Abstract] Quarterly Financial Information Disclosure [Abstract] Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] Humira H U M I R A [Member] Represents information pertaining to HUMIRA, a product of the entity. Annual rate of increase in the per capita cost of covered health care cost benefits assumed in the current year (as a percent) Defined Benefit Plan Health Care Cost Trend Rate Assumed Current Fiscal Year Represents the assumed health care cost trend rate for the current year used to measure the expected cost of benefits covered by the plan (gross eligible charges). Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities [Member] Payments of contingent consideration liabilities Payment for Contingent Consideration Liability, Operating Activities Actuarial loss (gain) Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax Aggregate Amount of Commercial Milestones Payable Aggregate Amount of Commercial Milestones Payable Aggregate Amount of Commercial Milestones Payable Acquisition costs Effective Income Tax Rate Reconciliation, Acquisition Costs Effective Income Tax Rate Reconciliation, Acquisition Costs Purchases of treasury stock (in shares) Shares repurchased (in shares) Treasury Stock, Shares, Acquired Thereafter Finance Lease, Liability, to be Paid, after Year Five Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Award Timing Disclosures [Line Items] Schedule of inventories Schedule of Inventory, Current [Table Text Block] Service cost Defined Benefit Plan, Service Cost Fair Value Measurement Frequency [Domain] Measurement Frequency [Domain] Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Acquired IPR&D and milestones Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff Debt designated as hedged item in fair value hedges gains (losses) recognized in the consolidated statements of earnings Increase (Decrease) in Fair Value of Hedged Item in Interest Rate Fair Value Hedge Debt, Credit Facilities and Commitments and Contingencies Debt Credit Facilities and Commitments and Contingencies Disclosure [Text Block] The entire disclosure for information about debt, credit facilities and commitments and contingencies. Net earnings attributable to AbbVie Inc. Net earnings attributable to AbbVie Inc. Total reclassifications, net of tax Net Income (Loss) Attributable to Parent Construction in progress Construction in Progress [Member] Other Other Accrued Liabilities, Current Summary of effective tax rate reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities, Current [Abstract] Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period All other, net Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Tax law changes and related structuring Effective Income Tax Rate Reconciliation, Tax Law Changes And Related Restructuring, Percent Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax law changes and related restructuring expenses. Preferred stock authorized (in shares) Preferred Stock, Shares Authorized Purchases of treasury stock Payments for Repurchase of Common Stock Adoption Date Trading Arrangement Adoption Date Senior notes due 2055 at 5.60% Senior notes due 2055 at 5.60 percent [Member] Senior notes due 2055 at 5.60 percent 4.40% senior notes due 2042 Senior Notes Due In 2042 At 4.40 Percent [Member] Represents the 4.40 percent long-term notes, which are due in 2042. Tax Credit Carryforward [Table] Tax Credit Carryforward [Table] Customer [Axis] Customer [Axis] Cash flows from financing activities Cash Provided by (Used in) Financing Activity, Continuing Operation [Abstract] Operating earnings Operating Income (Loss) Transfers of liabilities between the fair value measurement levels Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net [Abstract] Accumulated deficit Retained Earnings (Accumulated Deficit) 4.30% senior notes due 2036 Senior Notes 4.30 Percent Due 2036 [Member] Represents information pertaining to the 4.30% Unsecured Senior Notes Due 2036. Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) AbbVie Savings Plan AbbVie Savings Plan [Member] AbbVie Savings Plan [Member] Class of Stock [Axis] Class of Stock [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Definite-lived intangible assets impairment charges Impairment of Intangible Assets, Finite-Lived Effective Income Tax Rate Reconciliation, Cross-Border, Other, Amount Effective Income Tax Rate Reconciliation, Cross-Border, Other, Amount Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Other Deferred Tax Liabilities, Other Unamortized bond premiums Long Term Debt and Finance Lease Obligations Debt Instrument Unamortized Premiums Long Term Debt and Finance Lease Obligations Debt Instrument Unamortized Premiums Retirement Plan Type [Axis] Retirement Plan Type [Axis] Statement [Table] Statement [Table] Other expense, net Other Nonoperating Income (Expense) Actual return on plan assets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Business Combination, Recognized Asset Acquired, Investment in Debt and Equity Securities, Current Business Combination, Recognized Asset Acquired, Investment in Debt and Equity Securities, Current Deferred income taxes Total deferred taxes Deferred Income Tax Expense (Benefit) Lapse of statutes of limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Non-deductible expenses Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent Net revenues Revenue Benchmark [Member] Fair value step-up adjustment to inventories Business Combination, Fair Value Adjustment to Inventories Represents fair value step-up adjustments to inventories as of acquisition date. Foreign Tax Jurisdiction, Other Foreign Tax Jurisdiction, Other [Member] Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill Noncurrent finance lease liabilities Finance Lease, Liability, Noncurrent Background Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Asset allocation strategies and other holdings Other plan assets Defined Benefit Plan Other Assets [Member] Represents information relating to Defined Benefit Plan for other Assets. 4.95% senior notes due 2031 Senior Notes 4.95 Percent Due 2031 [Member] Senior Notes 4.95 Percent Due 2031 Investment, Type [Extensible Enumeration] Investment, Type [Extensible Enumeration] All Adjustments to Compensation All Adjustments to Compensation [Member] Amendment Flag Amendment Flag Tax benefit Share-Based Payment Arrangement, Expense, Tax Benefit Incremental vesting Share Based Compensation Arrangement by Share Based Payment Award Options Portion of Awards Vesting in Annual Increments Represents the portion of share options (or share units) granted during the period under equity-based awards, which will vest in annual increments. Shares reserved for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Other post-employment plans Other Postretirement Benefits Plan [Member] Schedule of defined benefit pension plan assets Schedule of Allocation of Plan Assets [Table Text Block] Long-term debt and lease obligations, gross Long Term Debt and Capital Lease Obligations, Gross Amount of long-term debt and capital lease obligations due after one year or beyond the normal operating cycle, if longer, before deduction of fair value hedges and unamortized discount. Termination Date Trading Arrangement Termination Date Collaborative Arrangements [Abstract] Collaborative Arrangements Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Raw materials Inventory, Raw Materials, Net of Reserves Intangible assets - In-process research and development Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Indefinite-Lived Sec 0.750 Senior Notes Due 2027 Sec 0.750 Senior Notes Due 2027 [Member] Sec 0.750 Senior Notes Due 2027 [Member] Weighted-average discount rate for operating leases Operating Lease, Weighted Average Discount Rate, Percent Summary of AbbVie stock option activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Accrued interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Business Combination, Acquiree's Revenue since Acquisition Date, Actual Business Combination, Acquiree's Revenue since Acquisition Date, Actual Weighted-average basic shares outstanding (in shares) Weighted-average basic shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Net amount of potential tax benefits that would impact the entity's effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Senior Notes Due in 2024 At 2.60 Percent [Member] Senior Notes Due in 2024 At 2.60 Percent [Member] Senior Notes Due in 2024 At 2.60 Percent Schedule of basic and diluted earnings per share, impact of two-class method Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Exercisable at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number All other countries Other Countries [Member] Represents information pertaining to other countries not specified anywhere. Segment Reporting [Abstract] Segment Reporting [Abstract] Effective Income Tax Rate Reconciliation, U.S. tax impact of branch accounting, net of FTC, Percent Effective Income Tax Rate Reconciliation, U.S. tax impact of branch accounting, net of FTC, Percent Effective Income Tax Rate Reconciliation, U.S. tax impact of branch accounting, net of FTC, Percent Anticipated annual amortization expense Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Tax benefit Reclassification from AOCI, Current Period, Tax Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Operating loss carryforwards with expiration through 2045 Operating Loss Carryforwards With Expiration Amount of operating loss carryforward with expiration day, before tax effects, available to reduce future taxable income under enacted tax laws. Debt Instrument, Unamortized Discount Debt Instrument, Unamortized Discount Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share December 2018 Stock Repurchase Authorization December 2018 Stock Repurchase Authorization [Member] December 2018 Stock Repurchase Authorization 2026 Finance Lease, Liability, to be Paid, Next Rolling 12 Months Product Liability Other Litigation Product Liability Other Litigation [Member] Product Liability Other Litigation 2031 to 2035 Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years 4.45% senior notes due 2046 Senior Notes 4.45 Percent Due 2046 [Member] Represents information pertaining to the 4.45% Unsecured Senior Notes Due 2046. Use of Estimates Use of Estimates, Policy [Policy Text Block] Accounts payable and accrued liabilities Liability, Defined Benefit Plan, Current Dividends paid Payments of Dividends Insider Trading Arrangements [Line Items] Interest income Investment Income, Interest and Dividend Weighted average fair value outstanding at the beginning of the period (in dollars per share) Weighted average fair value outstanding at the end of the period (in dollars per share) Share Based Compensation Arrangement by Share Based Payment Award, Non Option Equity Instruments Outstanding Weighted Average Grant Date Fair Value Represents the weighted average fair value of non-option equity instrument agreements awarded that validly exist and are outstanding, including vested instruments. 3.85% Senior Euro Notes due 2024 3.85% Senior Euro Notes due 2024 [Member] 3.85% Senior Euro Notes due 2024 Potential additional milestone payments Potential Payments under Agreement Certain Milestones The amount of additional payments that could be required for the achievement of certain milestones under a product agreement during the period. 2030 Lease, Liability, Payments, Due Year Five Amount of lessee's undiscounted obligation for lease payments for operating and finance leases, due in fifth fiscal year following latest fiscal year. 2030 Finance Lease, Liability, to be Paid, Year Five Acquired In-Process Research and Development In Process Research and Development, Policy [Policy Text Block] Revolving Credit Facility Maturing 2028 Revolving Credit Facility Maturing 2028 [Member] Revolving Credit Facility Maturing 2028 Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,838,678,628 shares issued as of December 31, 2025 and 1,831,594,494 as of December 31, 2024 Common Stock, Value, Outstanding Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Increase due to current year tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Business Combination, Recognized Liability Assumed, Long-Term Debt, Noncurrent Business Combination, Recognized Liability Assumed, Long-Term Debt, Noncurrent Increase due to acquisitions Unrecognized Tax Benefits, Increase Resulting from Acquisition Eye Care Eye Care [Member] Represents information pertaining to Eye Care, a key product portfolio of the entity. Counterparty Name [Axis] Counterparty Name [Axis] Deferred tax liabilities Components of Deferred Tax Liabilities [Abstract] Integration and restructuring charges Restructuring Reserve Cash Settled Restructuring Gains (Losses) The change in the restructuring reserve related to the amount of restructuring gains (losses) during the period that are expected to be cash settled. Debt securities Debt Securities, Available-for-Sale Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Net investment hedging activities, tax expense (benefit) Other Comprehensive Income (Loss), Net Investment Hedge, Tax Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on derivative instruments and nonderivative instruments designated and qualifying as net investment hedge. Non-NEOs Non-NEOs [Member] Corporate debt instruments Corporate Debt Securities [Member] Net asset (obligation) Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position Money Market Funds [Member]